Plain-English translation of NCT07572890 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing a regenerative therapy combined with glutathione to see if it can help improve how well your kidneys work. Researchers will compare this new treatment to an active control treatment and a placebo (inactive treatment) to understand whether the medication is safe and effective. The study involves about 100 adults with kidney disease.
Chronic kidney disease affects millions of people and can eventually lead to kidney failure requiring dialysis or transplant. This study exists because there is a need for new treatment options that might slow down kidney disease or help kidneys work better.
You likely qualify if…
You likely don't qualify if…
Over 12 months, you would receive monthly intravenous infusions (medicine through an IV) for the first 3 months, plus use a topical spray at home during that same period. You'll be randomly assigned to receive either the new treatment with glutathione, an active comparison treatment, or placebo. You'll have regular blood tests, physical exams, and check-ins to monitor how your kidneys are responding and watch for any side effects. If the treatment appears safe, some participants may have the option to cross over and receive the investigational therapy after the initial phase.
AI-generated summary from trial data · Jun 18, 2026 · Not medical advice
United States